Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.51 |
| ▸ | STAT3 | P40763 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ACLY | P53396 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2518669 | 0.89 | KMT2A (0.63) | KMT2AMEN1MAPK1PTGES2LMNA | |
| SCHEMBL7580127 | 0.82 | KMT2A (0.68) | KMT2AMEN1MAPK1PTGES2ACLY | |
| SCHEMBL7578507 | 0.80 | KEAP1 (0.53) | KMT2AMEN1MAPK1PTGES2LMNA | |
| SCHEMBL2616515 | 0.75 | LMNA (0.67) | STAT3LMNAPGRKEAP1ALDH1A1 | |
| SCHEMBL2516364 | 0.74 | MCOLN3 (0.68) | KMT2AMEN1PTGES2LMNAACLY | |
| SCHEMBL4192352 | 0.74 | NPC1 (0.58) | KMT2AMEN1MAPK1PTGES2ACLY | |
| SCHEMBL2519330 | 0.73 | PTGES2 (0.55) | KMT2AMEN1PTGES2STAT3LMNA | |
| SCHEMBL5694587 | 0.73 | PTGES2 (0.69) | KMT2AMEN1MAPK1PTGES2LMNA | |
| SCHEMBL13146531 | 0.73 | PGR (0.67) | KMT2AMEN1MAPK1PTGES2ACLY | |
| SCHEMBL7578178 | 0.72 | PTGES2 (0.64) | KMT2AMEN1MAPK1PTGES2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034827-B2 | Phenanthridine derivatives as bradykinin antagonists | Richter Gegeon Nyrt. (HU) | 2011-10-11 | — | — | US | disclosed |
| US-20090270411-A1 | PHENANTHRIDINE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270411-A1 | PHENANTHRIDINE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB2, BDKRB1, HRH2 | KMT2A 2282/4885MEN1 1415/4885MAPK1 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.